Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data

Checkpoint inhibitor therapy for metastatic melanoma has dramatically improved outcomes. Currently, 20 to 40% of treated patients achieve lengthy remissions. It is not clear whether patients in remission require ongoing therapy or if treatment can be safely discontinued. A retrospective chart review...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Leanne, Samlowski, Wolfram, Lopez-Flores, Ruby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138966/
https://www.ncbi.nlm.nih.gov/pubmed/35625881
http://dx.doi.org/10.3390/biomedicines10051144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138966/
https://www.ncbi.nlm.nih.gov/pubmed/35625881
http://dx.doi.org/10.3390/biomedicines10051144

Ejemplares similares